August 31st, 2005
The YaSheng Group (NASDAQ Other OTC: YHGG) through its
Academy of Science Research and Development Center has reported what it calls a breakthrough in Lysozyme DNA Technology. The
technology, which YaSheng has received China authorized patent (ZL03100582.9) and International patent (C12N15/62) is considered
an alternative to antibiotics. Other uses the new Lysozyme technology include an antiseptic for the food industry, a baby
food and milk additive, and as a less drastic measure to prevent cow Mastitis in dairy cows. The company through its Research
and Development Center is also looking at the technology as a low-cost alternative for the treatment of AIDs. The pharmaceutical
division of the company also indicated that it has produced transgenic Lysozyme plants as a herbal and food product with health
applications. Besides fighting off bacteria in animals and humans, Lysozyme has the potential to be used to improve the ability
of plants to resist bacteria.
YaSheng estimates that if Lysozyme was sold for $50.00
per gram, it could obtain $525 million in annual sales from its patent, which can be viewed at its web site. The YaSheng Group
has 135 subsidiaries, over 15,000 employees and assets of about $1.5 billion. The company is incorporated in Redwood City,
California.
